Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2201

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2201
---
 sell our products, we may not be able to generate product revenue.

We
have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates
ultimately receive regulatory approval, we expect to establish either an internal or external marketing and sales organization with technical
expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and,
to the extent we establish such organization in house, time consuming. We have no prior experience as a company in the marketing, sale
and distribution of pharmaceutical products and there are significant risks involved in establishing or managing a sales organization,
including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training
to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in
the development of our internal or external sales, marketing and distribution capabilities would adversely impact the commercialization
of these products. If we choose to collaborate with third parties that have direct sales forces and established distribution systems,
either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we may not
be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution
functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if
we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We
likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to
sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements
with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.

Risks
Related to Our Reliance on Third Parties For Our Product Development

We
rely on third parties to conduct all or certain aspects of our preclinical studies and clinical trials. If these third parties do not
successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to
obtain regulatory approval of or commercialize any potential product candidates.

We
depend upon third parties to conduct all or certain aspects of our preclinical studies and clinical trials, under agreements with universities,
medical institutions, CROs